Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

Official title

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on Direct Oral Anticoagulants - A Prospective Multicenter Study

Overview

Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin. Listed as core essential medicines by the World Health Organization, DOAC prescriptions have been surging worldwide. In Hong Kong, approximately 80,000 patients received DOACs from January 2009 through December 2022 according to the Hospital Authority registry. The widespread DOAC usage had created DOAC-specific clinical dilemmas that lack evidence-based treatment despite twenty years of prescribing experience. Ischemic stroke despite DOAC (IS-DOAC), in particular, may occur in up to 6% of DOAC users annually. Due to the in vivo anticoagulation effect, there had been concerns of intracerebral bleeding (ICH) with intravenous thrombolytic therapy (IVT) for acute IS-DOAC. Under the current guideline recommendations, most acute IS-DOAC are contraindicated to IVT (see Intravenous thrombolytic therapy), which resulted in only a small proportion of acute ISDOAC patients being able to receive IVT even if presented early. Nonetheless, our group found that majority of patients had a DOAC level of \<50ng/mL only 24 hours after DOAC cessation (see work done by us), a level deemed clinically negligible and safe for thrombolytic therapy. Together with evolving clinical evidence discussed below, IS-DOAC patients maybe unnecessarily barred from IVT, thus compromised functional recovery. With robust pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-DOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-DOAC.

Detailed description

In this prospective cohort study, the investigators aim to recruit consecutive DOAC users with IS-DOAC who meet the inclusion criteria. The investigators aim to determine the safety and efficacy of IVT among DOAC patients with acute ischemic stroke. It is hypothesized that compared to a matched cohort of patients with acute IS-DOAC excluded from IVT, IVT in IS-DOAC patients with a last-DOAC-ingestion of 12-48 hours improves neurological outcomes with an acceptable safety profile.

Interventions

• Drug alteplase or tenecteplase
  Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given

Primary outcome measures

• Presence of symptomatic intracerebral hemorrhage (ICH) [Time frame: up to 1 year]
• Modified Rankin Scale (mRS) [Time frame: 3 months after CVA]

Secondary outcome measures (3)

• Presence of asymptomatic ICH [Time frame: up to 1 year]
• Presence of hemorrhagic transformation [Time frame: up to 1 year]
• Presence of malignant cerebral edema [Time frame: up to 1 year]

Eligibility criteria

Inclusion criteria

• Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours
• Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or rivaroxaban (15mg or 20mg daily) 12-48 hours before presentation
• National Institute of Health Stroke Scale (NIHSS) ≥ 3
• Alberta Stroke Programme Early CT (ASPECT) score ≥ 6
• Pre-morbid modified Rankin Scale (mRS) ≤ 3
• Patients aged ≥ 18 years old

Exclusion criteria

• Initial CT brain showing intracranial haemorrhage
• Contraindications to IVT according to current guideline recommendations \[5\], except for the use of DOAC within 12-48 hours
• Patients with an estimated glomerular filtration rate of ≤ 30ml/min/1.73m2
• Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of < 100x109/L
• Patients with significant head injury immediately prior to presentation

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Hong Kong · 1 center

• Chinese University of Hong Kong — Hong Kong

Identifiers

NCT: NCT06241677 · CIRB-2023-167-1

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗